12:59 PM
Apr 26, 2019
 |  BioCentury  |  Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

ProNeurogen is tackling vascular cognitive impairment with angiotensin peptides

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill.

There are no therapies approved for vascular cognitive impairment. Multiple clinical trials have evaluated AD drugs, such as cholinesterase inhibitor donepezil and NMDA receptor antagonist memantine, in the indication. But researchers abandoned these repurposing attempts because the compounds did not consistently treat neuropsychiatric symptoms or improve the functional ability in patients.

According to ProNeurogen Inc., angiotensin-(1-7) binds and agonizes the MAS receptor expressed on neurons, microglia and vascular endothelial cells to increase blood flow to the brain, decrease levels of reactive oxygen species in the brain and cerebrovascular system, inhibit production of inflammatory cytokines in the brain and increase expression of neuroprotective proteins.

The company's lead compound is PNA1, the native form of the angiotensin-(1-7) peptide. In a 2017...

Read the full 727 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >